HighTower Advisors LLC Buys 53,382 Shares of The Oncology Institute, Inc. (NASDAQ:TOI)

HighTower Advisors LLC boosted its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 190.8% in the third quarter, Holdings Channel.com reports. The firm owned 81,362 shares of the company’s stock after acquiring an additional 53,382 shares during the period. HighTower Advisors LLC’s holdings in Oncology Institute were worth $27,000 as of its most recent SEC filing.

Separately, Tiff Advisory Services LLC boosted its holdings in Oncology Institute by 235.1% during the second quarter. Tiff Advisory Services LLC now owns 1,418,685 shares of the company’s stock worth $653,000 after purchasing an additional 995,280 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Trading Up 19.0 %

Shares of NASDAQ:TOI opened at $0.27 on Friday. The company’s 50-day moving average price is $0.24 and its two-hundred day moving average price is $0.35. The Oncology Institute, Inc. has a one year low of $0.13 and a one year high of $2.50. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The stock has a market capitalization of $20.09 million, a PE ratio of -0.34 and a beta of 0.43.

Insider Transactions at Oncology Institute

In other news, Director Brad Hively bought 250,000 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was bought at an average price of $0.17 per share, with a total value of $42,500.00. Following the completion of the acquisition, the director now owns 616,753 shares of the company’s stock, valued at $104,848.01. This represents a 68.17 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 9.50% of the stock is owned by company insiders.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.